Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on: October 24,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on:October 24,2023

Cost of cancer treatment can impact health of survivors

byMedical College of Georgia at Augusta UniversityDrs. Steven Coughlin, from left, Jorge Cortes and Biplab Datta. Credit: Michael Holahan, Augusta UniversityA significant number of people who ha

Updated on: December 18,2023

Cost of cancer treatment can impact health of survivors

byMedical College of Georgia at Augusta UniversityDrs. Steven Coughlin, from left, Jorge Cortes and Biplab Datta. Credit: Michael Holahan, Augusta UniversityA significant number of people who ha

Updated on:December 18,2023

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on: October 17,2023

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on:October 17,2023

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on: October 24,2023

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on:October 24,2023

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on: December 21,2023

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on:December 21,2023

As cancer survival rates are improving, heart problems in survivors are becoming more common

by Sean Tan,Monash UniversityCredit: Pixabay/CC0 Public DomainThe soft beeping of medical devices deepens the silence of the operating theater waiting room. Lying between monitors and intravenou

Updated on: January 04,2024

As cancer survival rates are improving, heart problems in survivors are becoming more common

by Sean Tan,Monash UniversityCredit: Pixabay/CC0 Public DomainThe soft beeping of medical devices deepens the silence of the operating theater waiting room. Lying between monitors and intravenou

Updated on:January 04,2024

AI model using daily step counts predicts unplanned hospitalizations during cancer therapy

byAmerican Society for Radiation OncologyCredit: Pixabay/CC0 Public DomainAn artificial intelligence (AI) model developed by researchers can predict the likelihood that a patient may have an unp

Updated on: January 04,2024

AI model using daily step counts predicts unplanned hospitalizations during cancer therapy

byAmerican Society for Radiation OncologyCredit: Pixabay/CC0 Public DomainAn artificial intelligence (AI) model developed by researchers can predict the likelihood that a patient may have an unp

Updated on:January 04,2024

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on: October 24,2023

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on:October 24,2023

Mayo Clinic researchers study immunity-boosting vaccine to target aggressive form of breast cancer

by From Mayo Clinic News Network, Mayo Clinic News NetworkThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Image

Updated on: December 18,2023

Mayo Clinic researchers study immunity-boosting vaccine to target aggressive form of breast cancer

by From Mayo Clinic News Network, Mayo Clinic News NetworkThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Image

Updated on:December 18,2023

New insights into colorectal cancer and E. coli

by Béatrice St-Cyr-Leroux,University of MontrealclbA and bft detection. a clbA and b bft presence in DNA extracted from fecal samples were detected using conventional qualitative PCR. M: marker;

Updated on: December 17,2023

New insights into colorectal cancer and E. coli

by Béatrice St-Cyr-Leroux,University of MontrealclbA and bft detection. a clbA and b bft presence in DNA extracted from fecal samples were detected using conventional qualitative PCR. M: marker;

Updated on:December 17,2023

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on: October 17,2023

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on:October 17,2023

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Updated on: October 15,2023

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Updated on:October 15,2023